161 related articles for article (PubMed ID: 34198725)
1. Promoter Methylation of
Daniunaite K; Bakavicius A; Zukauskaite K; Rauluseviciute I; Lazutka JR; Ulys A; Jankevicius F; Jarmalaite S
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34198725
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
[TBL] [Abstract][Full Text] [Related]
3. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
5. Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer.
Litovkin K; Joniau S; Lerut E; Laenen A; Gevaert O; Spahn M; Kneitz B; Isebaert S; Haustermans K; Beullens M; Van Eynde A; Bollen M
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1849-61. PubMed ID: 24938434
[TBL] [Abstract][Full Text] [Related]
6. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
[TBL] [Abstract][Full Text] [Related]
7. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
[TBL] [Abstract][Full Text] [Related]
8. Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer.
Lawrence MG; Pidsley R; Niranjan B; Papargiris M; Pereira BA; Richards M; Teng L; Norden S; Ryan A; Frydenberg M; Stirzaker C; Taylor RA; Risbridger GP; Clark SJ
Clin Epigenetics; 2020 Mar; 12(1):48. PubMed ID: 32188493
[TBL] [Abstract][Full Text] [Related]
9. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
[TBL] [Abstract][Full Text] [Related]
11. Altered methylation of multiple genes in carcinogenesis of the prostate.
Yamanaka M; Watanabe M; Yamada Y; Takagi A; Murata T; Takahashi H; Suzuki H; Ito H; Tsukino H; Katoh T; Sugimura Y; Shiraishi T
Int J Cancer; 2003 Sep; 106(3):382-7. PubMed ID: 12845678
[TBL] [Abstract][Full Text] [Related]
12. Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer.
Wu Y; Davison J; Qu X; Morrissey C; Storer B; Brown L; Vessella R; Nelson P; Fang M
Epigenetics; 2016 Apr; 11(4):247-58. PubMed ID: 26890304
[TBL] [Abstract][Full Text] [Related]
13. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
14. Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence.
Stott-Miller M; Zhao S; Wright JL; Kolb S; Bibikova M; Klotzle B; Ostrander EA; Fan JB; Feng Z; Stanford JL
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1331-9. PubMed ID: 24718283
[TBL] [Abstract][Full Text] [Related]
15. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
[TBL] [Abstract][Full Text] [Related]
16.
Holmes EE; Goltz D; Sailer V; Jung M; Meller S; Uhl B; Dietrich J; Röhler M; Ellinger J; Kristiansen G; Dietrich D
Clin Epigenetics; 2016; 8():104. PubMed ID: 27708722
[TBL] [Abstract][Full Text] [Related]
17. DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer.
Litovkin K; Van Eynde A; Joniau S; Lerut E; Laenen A; Gevaert T; Gevaert O; Spahn M; Kneitz B; Gramme P; Helleputte T; Isebaert S; Haustermans K; Bollen M
PLoS One; 2015; 10(6):e0130651. PubMed ID: 26086362
[TBL] [Abstract][Full Text] [Related]
18. PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.
Koch P; Petri M; Paradowska A; Stenzinger A; Sturm K; Steger K; Wimmer M
Prostate; 2009 Dec; 69(16):1751-62. PubMed ID: 19691131
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of DNA methylation in multifocal prostate cancer.
Serenaite I; Daniunaite K; Jankevicius F; Laurinavicius A; Petroska D; Lazutka JR; Jarmalaite S
Virchows Arch; 2015 Jan; 466(1):53-9. PubMed ID: 25369892
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer--novel predictor of biochemical recurrence after radical surgery.
Mitsui Y; Shiina H; Hiraki M; Arichi N; Hiraoka T; Sumura M; Honda S; Yasumoto H; Igawa M
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):487-96. PubMed ID: 22246902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
